HOYA Corporation (HOCPY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 28.72 means the share price is 28.72 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $49.8B is the value of all shares combined. Beta 0.60: the stock has moved about 40% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHOYA Corporation (HOCPY) trades at $148.98. HOYA Corporation is a global med-tech company providing life care and information technology products. Market cap: $49.8B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026HOCPY stock analysis for 2026: The stored analyst price target for HOYA Corporation is $201.94; its date is unknown, so no upside or downside is derived from it against the current price of $148.98. Key factors: analyst coverage, company fundamentals.
These figures come from statements filed 12 months ago — the most recent this company has published.
HOCPY: 2/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
HOYA Corporation (HOCPY) Healthcare & Pipeline Overview
HOYA Corporation, a Japanese med-tech leader, supplies life care products like eyeglass lenses and medical endoscopes, alongside IT products such as semiconductor components. With a $49.8B market cap and a 27.3% profit margin, HOYA leverages its diversified portfolio and global reach to maintain a competitive edge in the healthcare and technology sectors.
What Is the Investment Thesis for HOCPY?
With a market capitalization of $49.8B and a profit margin of 27.3%, HOYA demonstrates financial stability. Key value drivers include the growing demand for medical endoscopes and advanced optical components. Growth catalysts include expansion in emerging markets and continued innovation in its product lines. Potential risks include currency fluctuations and increased competition in the medical device market. The company's consistent dividend yield of 0.87% further enhances its appeal to income-seeking investors.
Based on FMP financials and quantitative analysis
HOCPY Key Highlights
Market Cap of $49.8B reflects HOYA's significant presence in the med-tech and IT sectors.
- P/E ratio of 28.72 indicates investor confidence in HOYA's earnings potential.
- Profit Margin of 27.3% showcases HOYA's efficient operations and strong pricing power.
- Gross Margin of 79.8% highlights the high value-added nature of HOYA's products and services.
- Beta of 0.60 suggests lower volatility compared to the overall market, appealing to risk-averse investors.
Who Are HOCPY's Competitors?
HOCPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ARGNF argenx SE | $1010.26 | 0.00% | $62.8B | — |
| CMXHF CSL Limited | $126.18 | 0.00% | $60.4B | — |
| LZAGF Lonza Group AG | $629.54 | -3.33% | $44.0B | — |
| MKGAF Merck KGaA | $151.95 | -3.35% | $66.1B | — |
| BDX Becton, Dickinson and Company | $176.42 | -1.88% | $48.6B | 705-pillar |
| ALC Alcon Inc. | $66.55 | -2.75% | $32.5B | 765-pillar |
| RMD ResMed Inc. | $218.27 | -0.60% | $31.7B | 935-pillar |
| MDLN Medline Inc. Class A Common Stock | $32.53 | +0.43% | $27.5B | 695-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HOCPY's Key Strengths?
Diversified product portfolio across healthcare and technology.
- Strong global presence and distribution network.
- High profit margin and gross margin.
- Technological expertise in optics and materials science.
What Are HOCPY's Weaknesses?
Exposure to currency fluctuations.
- Dependence on semiconductor industry cycles.
- Potential for increased competition in medical devices.
- Limited brand recognition compared to some competitors.
What Could Drive HOCPY Stock Higher?
Increasing demand for medical endoscopes due to minimally invasive surgery trends.
- Growth in the intraocular lens market driven by the aging population.
- Potential expansion into new geographic markets in Asia and Latin America by 2027.
- Continued innovation in semiconductor mask blanks for advanced chip manufacturing.
- Development and expansion of cloud-based healthcare solutions.
What Are the Key Risks for HOCPY?
Rich valuation — a P/E of 28.72 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Currency fluctuations affecting the value of ADR shares.
- Economic downturns impacting healthcare spending and demand for elective procedures.
- Increased competition in the medical device and semiconductor industries.
- Regulatory changes in healthcare and technology sectors.
- Dependence on the semiconductor industry cycle.
What Are the Growth Opportunities for HOCPY?
- Expansion in the Medical Endoscopy Market: The global medical endoscopy market is projected to reach $45 billion by 2028, driven by increasing demand for minimally invasive surgical procedures. HOYA's advanced endoscope technology and established distribution network position it to capture a significant share of this growing market. Investment in R&D to develop next-generation endoscopes with enhanced imaging capabilities will further solidify its competitive advantage.
- Growth in Intraocular Lenses (IOLs): The global IOL market is expected to reach $5 billion by 2027, fueled by the aging population and rising prevalence of cataracts. HOYA's innovative IOL designs and strong relationships with ophthalmic surgeons provide a solid foundation for growth in this sector. Strategic partnerships with eye clinics and hospitals can further expand its market reach.
- Penetration of Emerging Markets: Emerging markets, particularly in Asia and Latin America, offer significant growth opportunities for HOYA. Increasing healthcare spending and rising awareness of advanced medical technologies are driving demand for HOYA's products. Establishing local manufacturing facilities and distribution networks in these regions can enhance its competitiveness and market penetration.
- Advancements in Semiconductor Mask Blanks: The semiconductor industry is experiencing rapid growth, driven by demand for advanced chips in various applications. HOYA's mask blanks are essential components in semiconductor manufacturing. Investing in R&D to develop mask blanks for next-generation chips and expanding production capacity can capitalize on this growth opportunity. The global semiconductor market is projected to reach $1 trillion by 2030.
- Development of Cloud-Based Healthcare Solutions: The healthcare industry is increasingly adopting cloud-based solutions for data management and patient care. HOYA's ReadSpeaker and Kinnosuke cloud services can be expanded to offer comprehensive healthcare solutions. Developing partnerships with healthcare providers and integrating AI-powered analytics can enhance the value proposition of these services.
What Are HOCPY's Competitive Advantages?
- Technological expertise in optics and materials science.
- Diversified product portfolio across healthcare and technology sectors.
- Established global distribution network.
- Strong brand reputation for quality and innovation.
What Does HOCPY Do?
Founded in 1941 in Tokyo, Japan, HOYA Corporation initially focused on manufacturing optical lenses. Over the decades, HOYA strategically expanded its portfolio to become a diversified med-tech company. Today, HOYA operates globally, offering a wide array of products and services across two primary segments: Life Care and Information Technology. The Life Care segment includes eyeglass lenses, contact lenses (sold through its Eyecity retail chain), medical endoscopes, intraocular lenses, and surgical instruments. The Information Technology segment produces mask blanks and photomasks for semiconductor manufacturing, glass disks for hard disk drives, and imaging-related products. HOYA's evolution reflects its commitment to innovation and adaptation to changing market demands, solidifying its position as a key player in both the healthcare and technology industries.
What Products and Services Does HOCPY Offer?
- Develop and manufacture eyeglass and contact lenses for vision correction.
- Produce medical endoscopes for diagnostic and surgical procedures.
- Create intraocular lenses for cataract surgery.
- Manufacture laparoscopic surgical instruments.
- Provide automatic endoscope cleaning equipment.
- Supply mask blanks and photomasks for semiconductor chip manufacturing.
- Produce glass disks for hard disk drives.
- Offer speech synthesis software (ReadSpeaker) and cloud services.
How Does HOCPY Make Money?
- Manufacturing and sales of life care products (eyeglass lenses, contact lenses, medical devices).
- Manufacturing and sales of information technology products (semiconductor components, glass disks).
- Retail sales of contact lenses through its Eyecity chain.
- Software and cloud service subscriptions (ReadSpeaker, Kinnosuke, Yonosuke).
What Industry Does HOCPY Operate In?
HOYA Corporation operates within the rapidly evolving medical instruments and supplies industry, driven by technological advancements and increasing healthcare expenditure. The global medical device market is projected to reach $600 billion by 2026. HOYA's competitive landscape includes companies like ARGNF (Alcon), CMXHF (Carl Zeiss Meditec), LZAGF (EssilorLuxottica), LZAGY (EssilorLuxottica), and MKGAF (Nikon), each vying for market share through innovation and strategic partnerships. HOYA's diversified portfolio and global presence position it favorably to capitalize on these trends.
Who Are HOCPY's Key Customers?
- Eye care professionals (optometrists, ophthalmologists).
- Hospitals and surgical centers.
- Semiconductor manufacturers.
- Data storage companies.
- Businesses and organizations using speech synthesis software and cloud services.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● Covered by analysts
- ● Reported in JPY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 56 |
| 2026-08-26 | 56 |
| 2026-08-29 | 56 |
| 2026-09-01 | 56 |
| 2026-09-04 | 56 |
| 2026-09-07 | 56 |
| 2026-09-10 | 56 |
What changed?
The score has stayed at 56.
Over the same 18 days the stock moved -5.5%.
HOYA Corporation Financial Trajectory
HOYA Corporation (HOCPY) reported $1.69B in revenue for Q1 FY2027, reflecting 2.5% growth compared to the prior quarter. The company recorded net income of $433.7M, with diluted EPS of $1.30. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, HOCPY averaged $1.31 in diluted EPS.
Company Profile
HOYA Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Eiichiro Ikeda. HOCPY has traded publicly since 2007.
How HOYA Corporation Is Valued
HOYA Corporation carries a market capitalization of $49.8B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for HOYA Corporation stands at 25.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.5%, showing how much profit it generates from its asset base. HOCPY trades at a trailing price-to-earnings ratio of 28.72, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
HOYA Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 20.42 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
HOYA Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 7.3% above estimates on average.
HOCPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio across healthcare and technology.
- Strong global presence and distribution network.
- High profit margin and gross margin.
- Technological expertise in optics and materials science.
Bear Case
- Exposure to currency fluctuations.
- Dependence on semiconductor industry cycles.
- Potential for increased competition in medical devices.
- Limited brand recognition compared to some competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $1.69B | $434M | $1.30 |
| Q4 FY2026 | $1.64B | $359M | $1.07 |
| Q3 FY2026 | $1.62B | $607M | $1.79 |
| Q2 FY2026 | $1.55B | $367M | $1.07 |
Q1 FY2027 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from JPY at today's rate
HOCPY Latest News
-
PENTAX Medical and MAGENTIQ EYE Expand Global Partnership to Advance AI-Assisted Colonoscopy Worldwide
Yahoo! Finance: HOCPY News · Aug 26, 2026
-
HAYW or HOCPY: Which Is the Better Value Stock Right Now?
zacks.com · Aug 4, 2026
-
Hoya Q1 EPS $1.23 Beats $1.14 Estimate, Sales $1.605B Up From $1.479B YoY
benzinga · Jul 31, 2026
-
Hoya (HOCPY) Projected to Post Quarterly Earnings on Friday
defenseworld.net · Jul 24, 2026
HOCPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HOCPY.
Price Targets
Consensus target: $201.94
HOCPY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HOCPY; grades run from A+ (80-100) to F (below 30).
Latest News
PENTAX Medical and MAGENTIQ EYE Expand Global Partnership to Advance AI-Assisted Colonoscopy Worldwide
HAYW or HOCPY: Which Is the Better Value Stock Right Now?
Hoya Q1 EPS $1.23 Beats $1.14 Estimate, Sales $1.605B Up From $1.479B YoY
Hoya (HOCPY) Projected to Post Quarterly Earnings on Friday
Leadership: Eiichiro Ikeda
CEO
Eiichiro Ikeda serves as the CEO of HOYA Corporation, leading a global workforce of over 35,000 employees. His career spans several decades in the technology and healthcare sectors. Prior to becoming CEO, Ikeda held various leadership positions within HOYA, overseeing strategic planning, product development, and global operations. He holds advanced degrees in engineering and business administration, providing a strong foundation for his leadership role.
Track Record: Under Eiichiro Ikeda's leadership, HOYA Corporation has achieved significant milestones, including expansion into new markets and the successful launch of innovative products. He has focused on driving operational efficiency and fostering a culture of innovation within the company. His strategic decisions have contributed to HOYA's consistent financial performance and growth in key business segments.
HOYA Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. HOCPY is a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in HOYA Corporation more easily.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HOCP
HOCPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of transparency and regulatory oversight compared to listed companies. Investors should exercise caution and conduct thorough due diligence before investing.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in HOCPY.
- Lower liquidity can lead to price volatility and difficulty in trading.
- OTC Other tier status indicates a higher risk profile compared to listed companies.
- Potential for fraud or manipulation in the OTC market.
- Lack of regulatory oversight may expose investors to greater risks.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues involving the company.
- HOYA Corporation is a well-established company with a long operating history.
- The company has a significant market capitalization, suggesting a substantial business.
- HOYA Corporation is listed on the Tokyo Stock Exchange, indicating some level of regulatory compliance.
- The company has a diversified product portfolio and global presence.
- HOYA Corporation has a positive profit margin, suggesting financial stability.
What Investors Ask About HOYA Corporation (HOCPY) — Healthcare
Is HOCPY a good stock?
Stock Expert AI does not rate HOCPY buy, sell or hold. HOYA Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What revenue streams does HOYA Corporation have in healthcare?
HOYA Corporation's healthcare revenue streams are diversified across several key product lines. A significant portion comes from eyeglass and contact lenses, sold both directly and through its Eyecity retail chain.
What are the key factors to evaluate for HOCPY?
Evaluate HOCPY on fundamentals, analyst consensus, and risk factors. P/E: 28.72x vs the S&P 500's ~20-25x. Market Cap of $49.8B reflects HOYA's significant presence in the med-tech and IT sectors. Not financial advice.
How frequently does HOCPY data refresh on this page?
HOCPY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven HOCPY's recent stock price performance?
HOYA Corporation (HOCPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across healthcare and technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HOCPY overvalued or undervalued right now?
HOYA Corporation (HOCPY) trades at 28.72x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HOCPY?
Yes, most major brokerages offer fractional shares of HOYA Corporation (HOCPY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HOCPY's earnings and financial reports?
HOYA Corporation (HOCPY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for HOCPY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
No publishable V2 score is available for this stock yet.
Data provided for informational purposes only.
- OTC market data may have limited reliability.